alpha-aminopyridine has been researched along with Alzheimer Disease in 62 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (6.45) | 18.7374 |
1990's | 2 (3.23) | 18.2507 |
2000's | 4 (6.45) | 29.6817 |
2010's | 35 (56.45) | 24.3611 |
2020's | 17 (27.42) | 2.80 |
Authors | Studies |
---|---|
Alcaro, S; Bagetta, D; Bortolami, M; Carafa, C; Chiarotto, I; Colone, M; Costi, R; De Vita, D; Di Santo, R; Feroci, M; Messore, A; Pandolfi, F; Scipione, L; Stringaro, A | 1 |
Bard, J; Barnes, K; Chopra, R; Condon, J; Fan, K; Fobare, W; Hu, Y; Hui, Y; Johnson, M; Lovering, F; Malamas, MS; Manas, ES; Olland, A; Pangalos, MN; Reinhart, P; Robichaud, AJ; Solvibile, W; Turner, J | 1 |
Alvarez-Pérez, M; Chioua, M; Gandía, L; García, AG; González-Lafuente, L; López, MG; Marco-Contelles, J; Ríos, Cde L; Roda, JM; Romero, A; Samadi, A; Soriano, E; Villarroya, M | 1 |
Arahata, Y; Bundo, M; Ikenuma, H; Ito, K; Iwata, K; Kato, T; Kimura, Y; Nakamura, A; Nihashi, T; Okamura, N; Sakurai, K; Sakurai, T; Suzuki, K; Takeda, A; Washimi, Y; Yamaoka, A; Yanai, K | 1 |
Choe, YS; Chun, MY; Jang, H; Jeong, JH; Kim, HJ; Kim, JS; Kim, YJ; Lee, J; Moon, SH; Na, DL; Oh, JS; Oh, M; Oh, SJ; Roh, JH; Seo, SW; Woo, SY | 1 |
Akhtar, M; Hasan, N; Najmi, AK; Parvez, S; Zameer, S | 1 |
Dennison, J; Lohse, I; Mendez, A; Szeto, A; Volmar, CH; Wahlestedt, C | 1 |
Holtzman, DM; Hoyle, R; Long, J; Manis, M; Remolina Serrano, J; Shi, Y; Sullivan, PM; Wang, K | 1 |
Crider, A; House, A; Sandoval, K; Umbaugh, D; Witt, K | 1 |
Barkhausen, C; Blazhenets, G; Frings, L; Jost, WH; Meyer, PT; Rijntjes, M; Schröter, N; Weiller, C | 1 |
Chen, W; Fu, HR; Gao, YF; Wang, H; Wang, L; Wang, XD; Xu, XY; Xu, Y; Zhang, FF; Zhang, HT; Zhang, JG | 1 |
Choi, HD; Choi, JY; Jeong, YJ; Lee, HJ; Nam, KR; Oh, SJ; Shin, NR; Son, Y | 1 |
Chung, SJ; Kim, JS; Lee, CS; Lee, JH; Lee, SJ; Oh, JS; Oh, M; Oh, SJ; Roh, JH | 1 |
Bahri, MA; Balteau, E; Bastin, C; Besson, G; Cardone, P; Chylinski, D; Collette, F; Grignard, M; Lambert, C; Luxen, A; Maquet, P; Marzoli, D; Muto, V; Narbutas, J; Phillips, C; Salmon, E; Schmidt, C; Van Egroo, M; Vandeleene, N; Vandewalle, G | 1 |
Imabayashi, E; Matsuda, H; Mukai, T; Saitoh, Y; Takahashi, Y | 1 |
Akamatsu, G; Ito, H; Matsuda, H; Miwa, K; Sato, N; Shigemoto, Y; Wagatsuma, K; Yamao, T | 1 |
Akhtar, M; Hasan, N; Najmi, AK; Parvez, S; Yar, MS; Zameer, S | 1 |
Benedet, A; Bunai, T; Kang, MSP; Lussier, F; Matsudaira, T; Obi, T; Ouchi, Y; Pascoal, TA; Rosa-Neto, P; Savard, M; Terada, T; Therriault, J; Tissot, C; Tsukada, H; Wang, YT | 1 |
Kim, JS; Kim, M; Kim, SJ; Oh, JS; Oh, M; Oh, SJ; Park, JE; Roh, JH; Seo, SW; Shim, WH; Yun, J | 1 |
Ashour, NH; El Sayed, NS; El-Tanbouly, DM; Khattab, MM | 1 |
Crider, A; Lodholz, E; Polina, J; Sandoval, K; Schober, J; Scott, N; Walters, F; Witt, K | 1 |
Comley, RA; Gauthier, S; Guiot, MC; Guo, Q; Harada, R; Kang, MS; Massarweh, G; Mathotaarachchi, S; Ng, KP; Okamura, N; Pascoal, TA; Rosa-Neto, P; Shin, M; Soucy, JP; Therriault, J | 1 |
Arai, H; Funaki, Y; Furukawa, K; Furumoto, S; Harada, R; Hiraoka, K; Ishikawa, Y; Ishiki, A; Iwata, R; Kai, H; Kitamoto, T; Kudo, Y; Nakamura, T; Okamura, N; Sasano, H; Sato, N; Tago, T; Tashiro, M; Tomita, N; Watanuki, S; Yanai, K; Yoshikawa, T | 1 |
Cho, J; Furumoto, S; Ido, T; Jeong, HJ; Kang, H; Kang, JM; Lee, H; Lee, KM; Lee, SY; Lee, YB; Na, DL; Noh, Y; Okamura, N; Park, KH; Seo, S; Seong, JK; Shin, DH; Villemagne, VL; Woo, SH; Yanai, K; Yeon, BK | 1 |
Hosokawa, C; Ishii, K; Saigoh, K; Shirakawa, O; Takaya, M | 1 |
Cho, H; Choi, JY; Jagust, WJ; Jang, H; Jang, YK; Kim, HJ; Kim, JS; Lee, JS; Lyoo, CH; Moon, SH; Na, DL; Oh, M; Oh, SJ; Park, S; Rabinovici, GD; Ryu, YH; Seo, SW | 1 |
Liu, H; Luo, D; Luo, K | 1 |
Albay, R; Baglietto-Vargas, D; Glabe, CG; LaFerla, FM; Philipp, S; Reyes-Ruiz, JM; Sosna, J | 1 |
Chen, J; de Leon, MJ; Li, Y; Okamura, N; Pirraglia, E; Rusinek, H | 1 |
Almkvist, O; Arakawa, R; Chiotis, K; Ferreira, D; Halldin, C; Higuchi, M; Nordberg, A; Okamura, N; Shimada, H; Stenkrona, P; Stepanov, V; Takano, A; Varrone, A; Westman, E | 1 |
Arancio, O; Gulisano, W; Palmeri, A; Puzzo, D; Tropea, MR | 1 |
Nai, YH; Okamura, N; Tashiro, M; Watabe, H; Watanuki, S | 1 |
An, B; Hu, J; Huang, L; Li, X; Li, Z; Pan, T | 1 |
Feng, H; He, B; He, W; Li, S; Wang, C; Wei, M; Wu, X; Zeng, Z | 1 |
Ishii, K; Kubota, I; Shirakawa, O; Takaya, M | 1 |
Banks, WA; Crider, AM; Farr, SA; Morley, JE; Sandoval, KE; Witt, KA | 1 |
Aoki, I; Chang, Q; Furumoto, S; Higuchi, M; Ito, H; Iwata, N; Jang, MK; Ji, B; Kudo, Y; Lee, VM; Lewis, J; Maeda, J; Maruyama, M; Masamoto, K; Okamura, N; Ono, M; Sahara, N; Saido, TC; Shimada, H; Shinotoh, H; Suhara, T; Takano, H; Takashima, A; Trojanowski, JQ; Zhang, MR | 1 |
Böö, ÉL; Eguchi, Y; Farde, L; Fujiwara, H; Fukumura, T; Higuchi, M; Hirano, S; Ikoma, Y; Ito, H; Kawamura, K; Kimura, Y; Kodaka, F; Nagashima, T; Nogami, T; Sasaki, T; Seki, C; Shimada, H; Shinotoh, H; Suhara, T; Suzuki, M; Takahata, K; Takano, H | 1 |
Aihara, Y; Fujishiro, T; Furutsuka, K; Hashimoto, H; Hatori, A; Higuchi, M; Igarashi, N; Ito, T; Kawamura, K; Muto, M; Nemoto, K; Ono, M; Shiomi, S; Suhara, T; Takei, M; Xie, L; Yamasaki, T; Yui, J; Zhang, MR | 1 |
Gulyás, B; Häggkvist, J; Halldin, C; Marutle, A; Ni, R; Nordberg, A; Rodriguez-Vieitez, E; Tóth, M; Voytenko, L | 1 |
Higuchi, M; Ichise, M; Ikoma, Y; Ito, H; Kawamura, K; Kimura, Y; Kitamura, S; Sahara, N; Seki, C; Shimada, H; Shinotoh, H; Suhara, T; Takano, H; Zhang, MR | 1 |
Ågren, H; Kuang, G; Murugan, NA; Nordberg, A; Tu, Y | 1 |
Ashino, H; Bando, K; Chen, CJ; Farde, L; Higuchi, M; Ji, B; Kasahara, H; Minamizawa, T; Ono, M; Sano, H; Seki, C; Shiraishi, H; Suhara, T; Yamada, K; Zhang, MR | 1 |
Gao, M; Wang, M; Xu, Z; Zheng, QH | 1 |
Arai, H; Funaki, Y; Furukawa, K; Furumoto, S; Harada, R; Hiraoka, K; Inami, A; Ishikawa, Y; Ishiki, A; Iwata, R; Kudo, Y; Matsuda, R; Miyake, M; Okamura, N; Shidahara, M; Tago, T; Tashiro, M; Tomita, N; Watanuki, S; Yanai, K; Yoshikawa, T | 1 |
Arai, H; Baker, SL; Furukawa, K; Furumoto, S; Harada, R; Hiraoka, K; Ishiki, A; Jagust, WJ; Kudo, Y; Lockhart, SN; Okamura, N; Tashiro, M; Tomita, N; Watanuki, S; Yanai, K | 1 |
Halldin, C; Jia, Z; Svedberg, MM; Veldman, ER | 1 |
Aoki, M; Arai, H; Baba, T; Ezura, M; Funaki, Y; Furukawa, K; Furumoto, S; Harada, R; Hasegawa, T; Hiraoka, K; Ishiki, A; Iwata, R; Kikuchi, A; Kobayashi, J; Kobayashi, M; Kudo, Y; Mugikura, S; Okamura, N; Oshima, R; Sugeno, N; Takeda, A; Tano, O; Tashiro, M; Watanuki, S; Yanai, K; Yoshida, S | 1 |
Barnhart, TE; Betthauser, TJ; Christian, BT; Furumoto, S; Johnson, SC; Lao, PJ; Murali, D; Okamura, N; Stone, CK | 1 |
Farde, L; Jeppsson, F; Johnson, AE; Juréus, A; Neelissen, JA; Norman, H; Sandell, J; Ström, P; Svensson, SP; Wensbo, D | 1 |
Andersson, J; Cselényi, Z; Farde, L; Freund-Levi, Y; Halldin, C; Jönhagen, ME; Julin, P; Nyberg, S; Olsson, H; Svensson, S; Varnäs, K | 1 |
Klawe, C; Maschke, M | 1 |
Bergh, M; Jeppsson, F; Johnström, P; Juréus, A; Neelissen, J; Pyring, D; Sandell, J; Schou, M; Svensson, S; Swahn, BM | 1 |
Chioua, M; Estrada, M; Iriepa, I; Marco-Contelles, J; Moraleda, I; Pérez, C; Rodríguez-Franco, MI; Samadi, A | 1 |
Andersson, J; Cselényi, Z; Eriksdotter, M; Farde, L; Forsberg, A; Freund-Levi, Y; Halldin, C; Jeppsson, F; Johnström, P; Julin, P; Juréus, A; Sandell, J; Schou, M; Svensson, S; Swahn, BM; Varnäs, K | 1 |
Agoston, S; DeWit, DJ; Havinga, H; Pasma, J; Van Dam, GB; Wesseling, H | 1 |
Bores, GM; Brooks, KM; Camacho, F; Cunningham, DM; Davis, L; Fishkin, R; Hartman, HB; Li, M; Petko, W; Roehr, J; Rush, DK; Selk, DE; Smith, CP; Vargas, HM; Winslow, JT | 1 |
Böhm, M; Meesters, E; Meinhardt, A; Müller, WE; Pergande, G; Perovic, S | 1 |
Andreani, A; Leoni, A; Locatelli, A; Morigi, R; Pietra, C; Rambaldi, M; Villetti, G | 1 |
Blass, JP; Davidson, M; Davis, KL; Horvath, TB; Mohs, RC; Powchik, P; Zemishlany, Z | 1 |
Campbell, GA; Davis, KL; Haroutunian, V; Kanof, PD; Tsuboyama, GK | 1 |
Davis, KL; Hollander, E; Mohs, RC | 1 |
2 review(s) available for alpha-aminopyridine and Alzheimer Disease
Article | Year |
---|---|
Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound.
Topics: Alzheimer Disease; Aminopyridines; Analgesics; Animals; Humans; Neuroprotective Agents | 2009 |
Cholinergic approaches to the treatment of Alzheimer's disease.
Topics: 4-Aminopyridine; Alanine; Alzheimer Disease; Aminopyridines; Arecoline; Clinical Trials as Topic; Humans; Parasympathomimetics; Physostigmine; Piracetam; Pyrrolidines; Research Design; Succinimides; Synapses | 1986 |
5 trial(s) available for alpha-aminopyridine and Alzheimer Disease
Article | Year |
---|---|
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Cognition; Cognitive Dysfunction; Humans; Positron-Emission Tomography; Quinolines | 2022 |
Combination of automated brain volumetry on MRI and quantitative tau deposition on THK-5351 PET to support diagnosis of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aminopyridines; Brain; Cognitive Dysfunction; Diagnosis, Differential; Female; Healthy Volunteers; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Imaging; Positron-Emission Tomography; Prospective Studies; Quinolines; Radiopharmaceuticals; tau Proteins | 2021 |
Effects of 4-aminopyridine in elderly patients with Alzheimer's disease.
Topics: 4-Aminopyridine; Aged; Alzheimer Disease; Aminopyridines; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Random Allocation | 1984 |
4-Aminopyridine in the treatment of Alzheimer's disease.
Topics: 4-Aminopyridine; Aged; Aged, 80 and over; Alzheimer Disease; Aminopyridines; Brain; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Receptors, Cholinergic | 1988 |
Cholinergic approaches to the treatment of Alzheimer's disease.
Topics: 4-Aminopyridine; Alanine; Alzheimer Disease; Aminopyridines; Arecoline; Clinical Trials as Topic; Humans; Parasympathomimetics; Physostigmine; Piracetam; Pyrrolidines; Research Design; Succinimides; Synapses | 1986 |
56 other study(ies) available for alpha-aminopyridine and Alzheimer Disease
Article | Year |
---|---|
New deferiprone derivatives as multi-functional cholinesterase inhibitors: design, synthesis and in vitro evaluation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amino Acid Sequence; Aminopyridines; Catalytic Domain; Cholinesterase Inhibitors; Coordination Complexes; Deferiprone; Drug Design; Humans; Iron Chelating Agents; Molecular Docking Simulation; Pyrimidines; Structure-Activity Relationship | 2020 |
Novel pyrrolyl 2-aminopyridines as potent and selective human beta-secretase (BACE1) inhibitors.
Topics: Alzheimer Disease; Aminopyridines; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Brain; Crystallography, X-Ray; Humans; Models, Molecular; Structure-Activity Relationship | 2010 |
Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chloropyri
Topics: Acetylcholinesterase; Alzheimer Disease; Aminopyridines; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cholinergic Agents; Cholinesterase Inhibitors; Electrophorus; Horses; Humans; Models, Molecular; Neurons; Neuroprotective Agents; Nitriles; Pyridines; Vascular Diseases | 2010 |
Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum.
Topics: Aged; Alzheimer Disease; Aminopyridines; Amnesia; Aniline Compounds; Brain; Cognitive Dysfunction; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Positron-Emission Tomography; Quinolines; Radiopharmaceuticals; Severity of Illness Index; tau Proteins; Thiazoles | 2022 |
Roflumilast Reduces Pathological Symptoms of Sporadic Alzheimer's Disease in Rats Produced by Intracerebroventricular Streptozotocin by Inhibiting NF-κB/BACE-1 Mediated Aβ Production in the Hippocampus and Activating the cAMP/BDNF Signalling Pathway.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cyclopropanes; Disease Models, Animal; Glycogen Synthase Kinase 3 beta; Hippocampus; Maze Learning; Memory Disorders; NF-kappa B; Rats; Streptozocin | 2022 |
Low-Dose Chidamide Treatment Displays Sex-Specific Differences in the 3xTg-AD Mouse.
Topics: Alzheimer Disease; Aminopyridines; Animals; Female; Glucose; Humans; Male; Mice; Sex Characteristics | 2023 |
Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model.
Topics: Alzheimer Disease; Aminopyridines; Animals; Apolipoproteins E; Brain; Dietary Supplements; Disease Models, Animal; Humans; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Microglia; Neurodegenerative Diseases; Pyrroles; tau Proteins; Tauopathies | 2019 |
Somatostatin Receptor Subtype-4 Regulates mRNA Expression of Amyloid-Beta Degrading Enzymes and Microglia Mediators of Phagocytosis in Brains of 3xTg-AD Mice.
Topics: Alzheimer Disease; Aminopyridines; Animals; Brain; Catalase; Down-Regulation; Insulysin; Mice, Transgenic; Microglia; Neprilysin; Phagocytosis; Receptors, Somatostatin; RNA, Messenger; Scavenger Receptors, Class A; Sialic Acid Binding Ig-like Lectin 3; Thiourea; Up-Regulation | 2019 |
Tau Imaging in the 4-Repeat-Tauopathies Progressive Supranuclear Palsy and Corticobasal Syndrome: A 11C-Pyridinyl-Butadienyl-Benzothiazole 3 PET Pilot Study.
Topics: Aged; Alzheimer Disease; Aminopyridines; Benzothiazoles; Female; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Supranuclear Palsy, Progressive; tau Proteins | 2020 |
The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer's Disease: A Preclinical Study in APP/PS1 Transgenic Mice.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; Benzamides; Cerebral Cortex; Cyclopropanes; Depression; Disease Models, Animal; Hippocampus; Maze Learning; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phosphodiesterase 4 Inhibitors; Presenilin-1; Recognition, Psychology | 2020 |
Inhibition of Colony-Stimulating Factor 1 Receptor by PLX3397 Prevents Amyloid Beta Pathology and Rescues Dopaminergic Signaling in Aging 5xFAD Mice.
Topics: Aging; Alzheimer Disease; Aminopyridines; Amyloid; Amyloid beta-Peptides; Animals; Brain; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Hippocampus; Humans; Macrophage Colony-Stimulating Factor; Mice; Mice, Transgenic; Pyrroles; Receptors, Colony-Stimulating Factor; Signal Transduction | 2020 |
Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351.
Topics: Aged; Alzheimer Disease; Aminopyridines; Brain; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Positron-Emission Tomography; Pyridines; Quinolines; Radioactive Tracers; tau Proteins | 2020 |
Early brainstem [18F]THK5351 uptake is linked to cortical hyperexcitability in healthy aging.
Topics: Aged; Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Brain Stem; Cerebral Cortex; Cross-Sectional Studies; Early Diagnosis; Electroencephalography; Female; Fluorine Radioisotopes; Functional Neuroimaging; Healthy Aging; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Quinolines; Radiopharmaceuticals; tau Proteins; Transcranial Magnetic Stimulation | 2021 |
Visualization of Motor Cortex Involvement by 18F-THK5351 PET Potentially Strengthens Diagnosis of Amyotrophic Lateral Sclerosis.
Topics: Aged; Alzheimer Disease; Aminopyridines; Amyotrophic Lateral Sclerosis; Humans; Male; Motor Cortex; Positron-Emission Tomography; Quinolines | 2021 |
Centiloid scale analysis for
Topics: Alzheimer Disease; Aminopyridines; Humans; Positron-Emission Tomography; Quinolines | 2021 |
Roflumilast and tadalafil improve learning and memory deficits in intracerebroventricular Aβ1-42 rat model of Alzheimer's disease through modulations of hippocampal cAMP/cGMP/BDNF signaling pathway.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cyclic AMP; Cyclic GMP; Cyclopropanes; Cytokines; Gene Expression Regulation; Hippocampus; Male; Memory Disorders; Morris Water Maze Test; Oxidative Stress; Peptide Fragments; Random Allocation; Rats; Rats, Wistar; Tadalafil; Vasodilator Agents | 2021 |
Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aminopyridines; Aniline Compounds; Benzothiazoles; Brain Chemistry; Carbon Radioisotopes; Electron Transport Complex I; Entorhinal Cortex; Female; Fluorine Radioisotopes; Humans; Magnetic Resonance Imaging; Male; Mental Status and Dementia Tests; Middle Aged; Neuroimaging; Positron-Emission Tomography; Pyridazines; Pyridines; Radiopharmaceuticals; Severity of Illness Index; Symptom Assessment; tau Proteins; Thiazoles | 2021 |
Roflumilast ameliorates cognitive deficits in a mouse model of amyloidogenesis and tauopathy: Involvement of nitric oxide status, Aβ extrusion transporter ABCB1, and reversal by PKA inhibitor H89.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cognitive Dysfunction; Cyclopropanes; Disease Models, Animal; Hippocampus; Isoquinolines; Male; Mice; Nitric Oxide; Phosphodiesterase 4 Inhibitors; Protein Kinase Inhibitors; Streptozocin; Sulfonamides; Tauopathies | 2021 |
NNC 26-9100 increases Aβ1-42 phagocytosis, inhibits nitric oxide production and decreases calcium in BV2 microglia cells.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Calcium; Cell Line; Inflammation; Lipopolysaccharides; Mice; Microglia; Nitric Oxide; Peptide Fragments; Phagocytosis; Thiourea | 2021 |
Monoamine oxidase B inhibitor, selegiline, reduces
Topics: Aged; Alzheimer Disease; Aminopyridines; Autoradiography; Binding, Competitive; Brain; Cognitive Dysfunction; Drug Interactions; Female; Fluorine Radioisotopes; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Positron-Emission Tomography; Quinolines; Radiopharmaceuticals; Selegiline; Supranuclear Palsy, Progressive; tau Proteins | 2017 |
Correlations of
Topics: Aged, 80 and over; Alzheimer Disease; Aminopyridines; Gliosis; Humans; Male; Positron-Emission Tomography; Postmortem Changes; Quinolines; tau Proteins | 2018 |
Tau positron emission tomography using [
Topics: Aged; Alzheimer Disease; Aminopyridines; Amnesia; Brain; Cognitive Dysfunction; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Positron-Emission Tomography; Quinolines; Radiopharmaceuticals; Severity of Illness Index; tau Proteins | 2017 |
Tau accumulation in two patients with frontotemporal lobe degeneration showing different types of aphasia using 18F-THK-5351 positron emission tomography: a case report.
Topics: Aged; Alzheimer Disease; Aminopyridines; Aphasia, Primary Progressive; Brain; Female; Frontotemporal Lobar Degeneration; Humans; Middle Aged; Neuropsychological Tests; Positron-Emission Tomography; Quinolines; Radioactive Tracers; tau Proteins | 2018 |
Head to head comparison of [
Topics: Aged; Alzheimer Disease; Aminopyridines; Biological Transport; Carbolines; Female; Frontotemporal Dementia; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Quinolines; tau Proteins | 2018 |
Guanosine monophosphate reductase 1 is a potential therapeutic target for Alzheimer's disease.
Topics: Adaptor Proteins, Signal Transducing; Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Benzodioxoles; C-Reactive Protein; Databases, Genetic; Disease Models, Animal; Enzyme Inhibitors; Glycogen Synthase Kinase 3 beta; GMP Reductase; Mice; Molecular Targeted Therapy; Nerve Tissue Proteins; Phosphorylation; Proto-Oncogene Proteins c-met; Repressor Proteins; tau Proteins; Wnt Signaling Pathway | 2018 |
Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Amyloidogenic Proteins; Animals; Brain; Disease Models, Animal; Mice; Mice, Transgenic; Microglia; Neurons; Plaque, Amyloid; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 2018 |
Quantitative evaluation of tau PET tracers
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aminopyridines; Brain; Carbolines; Female; Humans; Male; Middle Aged; Positron-Emission Tomography; Quinolines | 2018 |
Dual tracer tau PET imaging reveals different molecular targets for
Topics: Aged; Alzheimer Disease; Aminopyridines; Brain; Carbon Radioisotopes; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Positron-Emission Tomography; Quinolines; Sweden; tau Proteins | 2018 |
Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Protein Precursor; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Cyclopropanes; Disease Models, Animal; Female; Humans; Male; Memory; Mice, Transgenic; Nootropic Agents; Phosphodiesterase Inhibitors; Random Allocation; Vardenafil Dihydrochloride | 2018 |
Investigation of the quantitative accuracy of low-dose amyloid and tau PET imaging.
Topics: Aged; Algorithms; Alzheimer Disease; Aminopyridines; Amyloid; Aniline Compounds; Artifacts; Benzothiazoles; Brain; Case-Control Studies; Female; Humans; Image Processing, Computer-Assisted; Male; Movement; Positron-Emission Tomography; Quinolines; Radiation Dosage; tau Proteins; Thiazoles; Young Adult | 2018 |
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Clioquinol; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Design; Humans; Ligands; Mice; Rats; Rolipram | 2019 |
Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Cyclic AMP; Cyclopropanes; Disease Models, Animal; Male; Memory; Mice, Transgenic; Nootropic Agents; Phosphodiesterase 4 Inhibitors | 2019 |
Progression of logopenic aphasia to frontotemporal dementia in an amyloid β-negative and
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Aphasia; Brain; Disease Progression; Female; Frontotemporal Dementia; Frontotemporal Lobar Degeneration; Humans; Middle Aged; Positron-Emission Tomography; Quinolines; Radioactive Tracers; tau Proteins | 2019 |
Somatostatin receptor subtype-4 agonist NNC 26-9100 mitigates the effect of soluble Aβ(42) oligomers via a metalloproteinase-dependent mechanism.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Blotting, Western; Cerebral Cortex; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Male; Maze Learning; Metalloproteases; Mice; Mice, Transgenic; Receptors, Somatostatin; Thiourea | 2013 |
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.
Topics: Age Factors; Aged; Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Aniline Compounds; Animals; Autoradiography; Benzothiazoles; Brain; Brain Mapping; Calcium-Binding Proteins; Carbon Isotopes; Disease Models, Animal; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; Humans; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microfilament Proteins; Middle Aged; Mutation; Positron-Emission Tomography; Protein Structure, Secondary; tau Proteins; Tauopathies; Thiazoles | 2013 |
Quantitative Analysis of Amyloid Deposition in Alzheimer Disease Using PET and the Radiotracer ¹¹C-AZD2184.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aminopyridines; Amyloid; Arteries; Benzothiazoles; Female; Humans; Kinetics; Male; Middle Aged; Models, Biological; Positron-Emission Tomography | 2014 |
Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzothiazoles; Brain; Carbon Radioisotopes; Humans; Mice; Positron-Emission Tomography; Quality Control; Radiochemistry; Radiopharmaceuticals; tau Proteins; Tissue Distribution | 2014 |
Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Benzothiazoles; Brain; Carbon Radioisotopes; Female; Gliosis; Male; Mice; Mice, Transgenic; Mutation; Plaque, Amyloid; Positron-Emission Tomography; Protein Binding; Radiopharmaceuticals | 2015 |
PET Quantification of Tau Pathology in Human Brain with 11C-PBB3.
Topics: Aged; Algorithms; Alzheimer Disease; Aminopyridines; Benzothiazoles; Brain; Computer Simulation; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Male; Models, Biological; Molecular Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; tau Proteins | 2015 |
Investigation of the Binding Profiles of AZD2184 and Thioflavin T with Amyloid-β(1-42) Fibril by Molecular Docking and Molecular Dynamics Methods.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Benzothiazoles; Drug Design; Elasticity; Fluorescent Dyes; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Peptide Fragments; Positron-Emission Tomography; Protein Binding; Radiopharmaceuticals; Static Electricity; Thiazoles | 2015 |
Distinct binding of amyloid imaging ligands to unique amyloid-β deposited in the presubiculum of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Amyloidogenic Proteins; Aniline Compounds; Autoradiography; Benzothiazoles; Humans; Imidazoles; In Vitro Techniques; Parahippocampal Gyrus; Plaque, Amyloid; Positron-Emission Tomography; Pyridines; Radiopharmaceuticals; Receptors, GABA; Thiazoles; Tomography, Emission-Computed, Single-Photon | 2015 |
Synthesis of a PET tau tracer [(11)C]PBB3 for imaging of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Benzothiazoles; Carbon Radioisotopes; Humans; Molecular Imaging; Molecular Structure; Positron-Emission Tomography; tau Proteins | 2015 |
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.
Topics: Alzheimer Disease; Aminopyridines; Animals; Autoradiography; Biotransformation; Brain; Hippocampus; Magnetic Resonance Imaging; Mice; Mice, Inbred ICR; Neurofibrillary Tangles; Positron-Emission Tomography; Quinolines; Radiation Dosage; Radiopharmaceuticals; tau Proteins; Tissue Distribution; White Matter | 2016 |
Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351.
Topics: Aged; Alzheimer Disease; Aminopyridines; Biomarkers; Brain; Brain Mapping; Case-Control Studies; Cognition; Fluorine Radioisotopes; Frontal Lobe; Humans; Positron-Emission Tomography; Quinolines; tau Proteins; Temporal Lobe; Time Factors | 2016 |
Amyloid binding properties of curcumin analogues in Alzheimer's disease postmortem brain tissue.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Autoradiography; Benzothiazoles; Curcumin; Diarylheptanoids; Female; Humans; Inhibitory Concentration 50; Male; Temporal Lobe | 2016 |
In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aminopyridines; Autoradiography; Basal Ganglia Diseases; Biomarkers; Brain; Brain Mapping; Diagnosis, Differential; Female; Humans; Male; Mental Status Schedule; Middle Aged; Positron-Emission Tomography; Quinolines; Radiopharmaceuticals; tau Proteins | 2016 |
In Vivo Comparison of Tau Radioligands
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aminopyridines; Aniline Compounds; Biomarkers; Brain; Female; Humans; Isotope Labeling; Male; Metabolic Clearance Rate; Middle Aged; Molecular Imaging; Positron-Emission Tomography; Protein Binding; Quinolines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; tau Proteins; Tissue Distribution | 2017 |
AZD2184: a radioligand for sensitive detection of beta-amyloid deposits.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Aniline Compounds; Animals; Autoradiography; Benzothiazoles; Brain; Carbon Radioisotopes; Competitive Bidding; Humans; Male; Mice; Mice, Transgenic; Mutation; Plaque, Amyloid; Positron-Emission Tomography; Presenilin-1; Protein Binding; Radioligand Assay; Rats; Rats, Sprague-Dawley; Thiazoles; Tritium | 2009 |
Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184.
Topics: Adult; Aged; Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Benzothiazoles; Carbon Radioisotopes; Case-Control Studies; Female; Humans; Male; Middle Aged; Positron-Emission Tomography; Young Adult | 2009 |
Synthesis and evaluation of pyridylbenzofuran, pyridylbenzothiazole and pyridylbenzoxazole derivatives as ¹⁸F-PET imaging agents for β-amyloid plaques.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Benzofurans; Benzothiazoles; Benzoxazoles; Brain; Contrast Media; Fluorine Radioisotopes; Humans; Mice; Mice, Transgenic; Positron-Emission Tomography; Radiopharmaceuticals; Structure-Activity Relationship | 2012 |
Pyridonepezils, new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease: synthesis, biological assessment, and molecular modeling.
Topics: Acetylcholinesterase; Alzheimer Disease; Aminopyridines; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Enzyme Assays; Humans; Indans; Models, Biological; Models, Molecular; Nitriles; Permeability; Piperidines; Protein Binding; Pyridines; Structure-Activity Relationship | 2012 |
Low background and high contrast PET imaging of amyloid-β with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Aniline Compounds; Animals; Benzothiazoles; Benzoxazoles; Binding Sites; Brain; Carbon Radioisotopes; Case-Control Studies; Female; Humans; Magnetic Resonance Imaging; Male; Mice; Mice, Transgenic; Middle Aged; Positron-Emission Tomography; Protein Binding; Radioligand Assay; Radiopharmaceuticals; Sensitivity and Specificity; Thiazoles | 2013 |
Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease.
Topics: Acetylcholinesterase; Administration, Oral; Alzheimer Disease; Aminopyridines; Animals; Avoidance Learning; Brain; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Corpus Striatum; Dopamine; Female; Humans; Hypothermia, Induced; Kinetics; Male; Maze Learning; Memory; Mice; Mice, Inbred Strains; Ovariectomy; Prosencephalon; Rats; Rats, Wistar; Scopolamine; Social Behavior; Space Perception; Time Factors | 1997 |
Pharmacological intervention in age-associated brain disorders by Flupirtine: Alzheimer's and prion diseases.
Topics: Aging; Alzheimer Disease; Amino Acid Sequence; Aminopyridines; Amyloid beta-Peptides; Animals; Apoptosis; Calcium; Cell Survival; Cells, Cultured; Glutamates; Molecular Sequence Data; Neurons; Neuroprotective Agents; Peptide Fragments; Prion Diseases; Prions; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; Time Factors | 1998 |
4-Aminopyridine derivatives with antiamnesic activity.
Topics: 4-Aminopyridine; Alzheimer Disease; Aminopyridines; Amnesia; Animals; Avoidance Learning; Carbon Dioxide; Indoles; Male; Mice; Nootropic Agents; Piracetam | 2000 |
Animal models of Alzheimer's disease: behavior, pharmacology, transplants.
Topics: 4-Aminopyridine; Alzheimer Disease; Aminopyridines; Animals; Behavior, Animal; Brain; Disease Models, Animal; Fetus; Growth Substances; Humans; Nerve Growth Factors; Nerve Tissue; Nerve Tissue Proteins; Nervous System Diseases; Norepinephrine; Parasympathetic Nervous System; Physostigmine; Somatostatin | 1986 |